MedTrace Logo

Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)

NCT04931563 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 277

Last updated 2026-05-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).

Conditions

  • Active Systemic Lupus Erythematosus

Interventions

BIOLOGICAL

Anifrolumab

Intravenous infusion (IV)

DRUG

placebo

Intravenous infusion (IV)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2025-04-07
Completion
2025-06-10

Countries

  • China
  • Hong Kong
  • Philippines
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04931563 on ClinicalTrials.gov